Previous 10 | Next 10 |
ROCKVILLE, Md. , Aug. 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its op...
ROCKVILLE, Md. , July 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today receipt, on June 28, 2019 , of notificati...
ROCKVILLE, Md. , July 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today receipt, on June 28, 2019 , of notificati...
Synthetic Biologics, Inc. (SYN) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Vincent Perrone – Director-Corporate Communication Steven Shallcross – Chief Executive and Financial Officer Conference Call Participants Presentation ...
Synthetic Biologics (NYSEMKT: SYN ): Q1 GAAP EPS of -$0.25. More news on: Synthetic Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
ROCKVILLE, Md. , May 8, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported...
ROCKVILLE, Md. , April 30, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its opera...
Synthetic Biologics Inc. (SYN) Q4 2018 Earnings Conference Call February 27, 2019 16:30 ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - CEO & CFO Vince Wacher - Head, Product & Corporate Development Conference Call Parti...
Synthetic Biologics (NYSEMKT: SYN ): FY GAAP EPS of -$4.06. More news on: Synthetic Biologics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
ROCKVILLE, Md. , Feb. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a clinical programs update and report...
News, Short Squeeze, Breakout and More Instantly...
Synthetic Biologics Inc. Company Name:
SYN Stock Symbol:
NYSE Market:
Synthetic Biologics Inc. Website:
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and branding elements were introduced to better ref...
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from collaborators at Fund...
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical...